Effects of Food and Drug Administration-approved medications for Alzheimer's disease on clinical progression

Alzheimer's and Dementia

Volumn 8, Issue 3, 2012, Pages 180-187

  Mielke, Michelle M ^a   Leoutsakos, Jeannie Marie ^a   Corcoran, Chris D ^b   Green, Robert C ^c   Norton, Maria C ^b   Welsh Bohmer, Kathleen A ^d   Tschanz, Joann T ^b   Lyketsos, Constantine G ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UTAH STATE UNIVERSITY   (United States)

^c BOSTON UNIVERSITY   (United States)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

APOE; Cholinesterase inhibitor; Disease progression; Incident Alzheimer's disease; Memantine; Population based; Sex

Indexed keywords

APOLIPOPROTEIN E; APOLIPOPROTEIN E4; DONEPEZIL; GALANTAMINE; MEMANTINE; RIVASTIGMINE;

AGED; ALLELE; ALZHEIMER DISEASE; ARTICLE; CLINICAL DEMENTIA RATING SUM OF BOXES; CLINICAL OBSERVATION; DISEASE COURSE; DRUG APPROVAL; DRUG EXPOSURE; DRUG USE; FEMALE; FOOD AND DRUG ADMINISTRATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; ONSET AGE; PREDICTOR VARIABLE; PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; SEX DIFFERENCE; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; APOLIPOPROTEIN E4; CHOLINESTERASE INHIBITORS; COHORT STUDIES; COMMUNITY HEALTH PLANNING; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; HUMANS; MALE; MEMANTINE; NEUROPSYCHOLOGICAL TESTS; OBSERVATION; PSYCHIATRIC STATUS RATING SCALES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84860477978     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2011.02.011     Document Type: Article

References (33)

1. S.B. Dybicz, D.J. Keohane, W.G. Erwin, T. McRae, and S.N. Shah Patterns of cholinesterase-inhibitor use in the nursing home setting: a retrospective analysis Am J Geriatr Pharmacother 4 2006 154 160 (Pubitemid 44057811)
2. N. Herrmann, and K.L. Lanctot Pharmacologic management of neuropsychiatric symptoms of Alzheimer disease Can J Psychiatry 52 2007 630 646 (Pubitemid 350085594)
3. L. Mucha, S. Shaohung, B. Cuffel, T. McRae, T.L. Mark, and M. Del Valle Comparison of cholinesterase inhibitor utilization patterns and associated health care costs in Alzheimer's disease J Manag Care Pharm 14 2008 451 461
4. Zhu CW, Livote EE, Kahle-Wrobleski K, Scarmeas N, Albert M, Brandt J, Blacker D, Sano M, Stern Y. Longitudinal Medication Usage in Alzheimer Disease Patients. Alzheimer Dis Assoc Disord (in press).
5. B.S. Black, J. Kasper, J. Brandt, A.D. Shore, P. German, and L. Burton Identifying dementia in high-risk community samples: the memory and medical care study Alzheimer Dis Assoc Disord 17 2003 9 18 (Pubitemid 36288241)
6. I.H. Zuckerman, P.T. Ryder, L. Simoni-Wastila, T. Shaffer, M. Sato, and L. Zhao Racial and ethnic disparities in the treatment of dementia among Medicare beneficiaries J Gerontol B Psychol Sci Soc Sci 63 2008 S328 S333
7. O.L. Lopez, J.T. Becker, S. Wisniewski, J. Saxton, D.I. Kaufer, and S.T. DeKosky Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease J Neurol Neurosurg Psychiatry 72 2002 310 314
8. D.S. Geldmacher, G. Provenzano, T. McRae, V. Mastey, and J.R. Ieni Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease J Am Geriatr Soc 51 2003 937 944 (Pubitemid 36871141)
9. R.H. Foster, and G.L. Plosker Donepezil. Pharmacoeconomic implications of therapy Pharmacoeconomics 16 1999 99 114
10. M.S. Mega, D.M. Masterman, S.M. O'Connor, T.R. Barclay, and J.L. Cummings The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease Arch Neurol 56 1999 1388 1393 (Pubitemid 29519856)
11. J.C. Breitner, B.W. Wyse, J.C. Anthony, K.A. Welsh-Bohmer, D.C. Steffens, and M.C. Norton APOE-epsilon 4 count predicts age when prevalence of AD increases, then declines: the Cache County Study Neurology 53 1999 321 331 (Pubitemid 29344354)
12. Tschanz JT, Corcoran CD, Schwartz S, Treiber K, Green R, Norton MC, et al. Progression of cognitive, functional and neuropsychiatric symptom domains in a population cohort with Alzheimer's dementia: The Cache County Dementia Progression Study. J Am Geriatr Soc (in press).
13. APA Diagnostic and statistical manual of mental disorders 3rd edn Rev. ed 1987 American Psychiatric Association, Washington, DC
14. C. Hughes, L. Berg, W.L. Danziger, L.A. Coben, and R.L. Martin A new clinical scale for the staging of dementia Br J Dement 140 1982 566 572 (Pubitemid 12124384)
15. C.G. Lyketsos, E. Galik, C. Steele, M. Steinberg, A. Rosenblatt, and A. Warren The General Medical Health Rating: a bedside global rating of medical comorbidity in patients with dementia J Am Geriatr Soc 47 1999 487 491 (Pubitemid 29181378)
16. G. McKhann, D. Drachman, M. Folstein, R. Katzman, D. Price, and E.M. Stadlan Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease Neurology 34 1984 939 944 (Pubitemid 14076461)
17. M.F. Folstein, S.E. Folstein, and P.R. McHugh "Mini-Mental state." A practical method for grading the cognitive state of patients for the clinician J Psychiatr Res 12 1975 189 198
18. R.C. Mohs, J. Schmeidler, and M. Aryan Longitudinal studies of cognitive, functional and behavioural change in patients with Alzheimer's disease Stat Med 19 2000 1401 1409 (Pubitemid 30346233)
19. M.M. Mielke, P.B. Rosenberg, J. Tschanz, L. Cook, C. Corcoran, and K.M. Hayden Vascular factors predict rate of progression in Alzheimer disease Neurology 69 2007 1850 1858 (Pubitemid 350071146)
20. J.C. Morris Clinical dementia rating: a reliable and valid diagnostic and staging measure for dementia of the Alzheimer type Int Psychogeriatr 9 Suppl 1 1997 173 176 discussion 177-8 (Pubitemid 28045357)
21. V.N. Pavlik, R.S. Doody, P.J. Massman, and W. Chan Influence of premorbid IQ and education on progression of Alzheimer's disease Dement Geriatr Cogn Disord 22 2006 367 377 (Pubitemid 44651453)
22. P.P. Zandi, J.C. Anthony, K.M. Hayden, K. Mehta, L. Mayer, and J.C. Breitner Reduced incidence of AD with NSAID but not H2 receptor antagonists: the Cache County Study Neurology 59 2002 880 886
23. S.D. Rountree, W. Chan, V.N. Pavlik, E.J. Darby, S. Siddiqui, and R.S. Doody Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease Alzheimers Res Ther 1 2009 7
24. K.M. Mehta, M. Yin, C. Resendez, and K. Yaffe Ethnic differences in acetylcholinesterase inhibitor use for Alzheimer disease Neurology 65 2005 159 162 (Pubitemid 40967798)
25. H. Aguero-Torres, L. Fratiglioni, Z. Guo, M. Viitanen, and B. Winblad Prognostic factors in very old demented adults: a seven-year follow-up from a population-based survey in Stockholm J Am Geriatr Soc 46 1998 444 452 (Pubitemid 28188517)
26. S. Ferris, R. Lane, N. Sfikas, B. Winblad, M. Farlow, and H.H. Feldman Effects of gender on response to treatment with rivastigmine in mild cognitive impairment: a post hoc statistical modeling approach Gend Med 6 2009 345 355
27. A.S. Rigaud, L. Traykov, F. Latour, R. Couderc, F. Moulin, and F. Forette Presence or absence of at least one epsilon 4 allele and gender are not predictive for the response to Donepezil treatment in Alzheimer's disease Pharmacogenetics 12 2002 415 420 (Pubitemid 34816421)
28. M.E. Rhodes, S.M. O'Toole, S.L. Wright, R.K. Czambel, and R.T. Rubin Sexual diergism in rat hypothalamic-pituitary-adrenal axis responses to cholinergic stimulation and antagonism Brain Res Bull 54 2001 101 113 (Pubitemid 32156921)
29. V.N. Luine, K.J. Renner, and B.S. McEwen Sex-dependent differences in estrogen regulation of choline acetyltransferase are altered by neonatal treatments Endocrinology 119 1986 874 878 (Pubitemid 16048849)
30. S. Avissar, Y. Egozi, and M. Sokolovsky Studies on muscarinic receptors in mouse and rat hypothalamus: a comparison of sex and cyclical differences Neuroendocrinology 32 1981 295 302 (Pubitemid 11098893)
31. H. Hortnagl, L. Hansen, G. Kindel, B. Schneider, A. el Tamer, and I. Hanin Sex differences and estrous cycle-variations in the AF64A-induced cholinergic deficit in the rat hippocampus Brain Res Bull 31 1993 129 134 (Pubitemid 23102834)
32. R.H. Wang, D. Schorer-Apelbaum, and M. Weinstock Testosterone mediates sex difference in hypothermia and cholinesterase inhibition by rivastigmine Eur J Pharmacol 433 2001 73 79 (Pubitemid 34038083)
33. R.H. Wang, C. Bejar, and M. Weinstock Gender differences in the effect of rivastigmine on brain cholinesterase activity and cognitive function in rats Neuropharmacology 39 2000 497 506 (Pubitemid 30052938)